Safety and Immunogenicity of an HIV‐1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV‐1–Infected Women | Zendy

Daniel Johnson | Zendy; Elizabeth J. McFarland | Zendy; Petronella Muresan | Zendy; Terence Fenton | Zendy; James McNamara | Zendy; Jennifer S. Read | Zendy; Elizabeth Hawkins | Zendy; Pamela Bouquin | Zendy; Scharla Estep | Zendy; Georgia D. Tomaras | Zendy; Carol Ann Vincent | Zendy; Mobeen H. Rathore | Zendy; Ann J. Melvin | Zendy; Sanjay Gurunathan | Zendy; John S. Lambert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Immunogenicity of an HIV‐1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV‐1–Infected Women

Author(s) -

Daniel Johnson,

Elizabeth J. McFarland,

Petronella Muresan,

Terence Fenton,

James McNamara,

Jennifer S. Read,

Elizabeth Hawkins,

Pamela Bouquin,

Scharla Estep,

Georgia D. Tomaras,

Carol Ann Vincent,

Mobeen H. Rathore,

Ann J. Melvin,

Sanjay Gurunathan,

John S. Lambert

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/498163

Subject(s) - immunogenicity , virology , medicine , human immunodeficiency virus (hiv) , immunology , recombinant dna , antibody , biology , biochemistry , gene

Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1). HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks. The vaccines were safe. Lymphoproliferative responses were detected at > or =2 time points in 44%-56% of vaccinees and none of the placebo recipients. A cytotoxic T lymphocyte response on at least 1 occasion was detected in 62.5% of infants in cohort 1 (10(6.08) median tissue culture dose [TCID(50)] vaccine formulation) and 44% of infants in cohort 2 (10(6.33) TCID(50) vaccine formulation). Rare mucosal immunoglobulin A responses and no measurable vaccine-elicited serum antibodies were detected. In children, vCP205 appeared to be safe and immunogenic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research